AIRelated Layoffs and Stock Performance Not Always a Positive Signal Fed Rate Hike Expectations Surge Futures Market Prices in Increase as Early as December Southwest Airlines CEO No Demand Drop Despite Higher Fares Booking Holdings Launches Unified BKNG Ads Platform to Streamline CrossBrand Advertising Microsoft and Anthropic in Talks for Custom AI Chip Deal After 5 Billion Investment Trump Family Dynamics in Focus as Former President Skips Sons Wedding Huntington Ingalls Industries Inc HII Q1 2026 Earnings Adjusted EPS Slightly Beats Estimates Amid Robust Defense Demand VZ Q1 2026 Earnings EPS Beats Estimates by 381 as Stock Eases Back on Mixed Signals CLS Q1 2026 Earnings Beat and Raise as Celestica Delivers Strong EPS Surprise NOK Q1 2026 Earnings EPS Surpasses Estimates by 2285 Shares Jump TRMB Q1 2026 Earnings EPS Surpasses Estimates by 79 Amid Strong Operational Execution Belden Inc BDC Q1 2026 Earnings EPS Surges Past Expectations on Operational Strength Protalix BioTherapeutics PLX Consolidates Near Support After Mild Decline Jena Acquisition Corporation II JENA Holds Steady Near 1029 as SPAC Trading Activity Remains Muted The Hartford Insurance Group HIG Edges Lower Consolidation Within Established Technical Range Diversified Healthcare Trust DHC Edges Lower as Support Levels Come into Focus Otis Worldwide OTIS Holds Near 72 as Minor Decline Tests Support Zone Vanguard Corporate Releases Economic Outlook for Canada A ForwardLooking Assessment Optex Systems Q1 2026 Earnings EPS of 003 as Stock Gains 173 ESAB Corporation ESAB Holds Steady as Shares Edge Higher Testing Key Resistance Roadzen Inc RDZN Consolidates at 19 as Stock Hovers Between Key Support and Resistance Harvard Ave Acquisition Unit HAVAU Inches Higher Above Support Immunovant IMVT Holds Steady Near Support as Traders Await Catalyst Oxford Lane Capital Corp Preferred Shares OXLCP Hold Steady at 2495 Amid Flat Trading A SPAC III Acquisition Corp Unit ASPCU Rises 378 as Momentum Builds Toward Key Resistance REX American Resources REX Slips 468 as Shares Test Key Support Levels Immix Biopharma IMMX Edges Lower in Consolidation Phase Eyes Key Support at 829